DETO2X-AMI: Supplemental O2 Provides No Benefit for Patients with Suspected Infarction

According to this study simultaneously presented at the European Society of Cardiology Congress 2017 and published in the New England Journal of Medicine, routinely providing supplemental oxygen therapy to patients without hypoxemia with suspected acute myocardial infarction did not result in a reduction in the 1-year risk of all-cause mortality when compared with patients receiving ambient air.

DETO2X-AMI: el O2 suplementario no aporta beneficios en pacientes con sospecha de infarto

There was no benefit of oxygen therapy in any of the prespecified subgroups, including patients with confirmed ongoing infarction. The extent of myocardial injury (as assessed by cardiac troponin T levels) was no different between patients who received oxygen and those who received ambient air.

 

According to the authors of this study, there was initial resistance from physicians to omitting the provision of oxygen to patients with suspected infarction, despite the absolute lack of evidence supporting such strategy. The provision of oxygen is most likely one of those things that we keep doing because it has always been done. The use of supplemental oxygen is recommended by clinical practice guidelines, mostly based on expert opinion.


Read also: CTO in patients with acute myocardial infarction increases long term mortality”.


To address this question, the study assessed 6629 patients enrolled in the SWEDEHEART registry who were admitted within 6 hours from the onset of symptoms suggestive of acute myocardial infarction, with an oxygen saturation higher than 90% and electrocardiogram findings suggestive of ischemia. Patients were randomized to 6 L/min of oxygen for 6 to 12 hours or ambient air.

 

At 1 year, the rate of all-cause death was 5.0% for patients randomized to oxygen and 5.1% for patients treated with ambient air (p = 0.80). There was no difference as regards combined endpoints either.


Read also: Primary angioplasty and multivessel lesions: how should we proceed?”


The priority should be getting these patients as quickly as possible to the catheterization laboratory rather than wasting time with supplemental oxygen if ambient air provides adequate saturation.

 

European guidelines were updated recently (2017) and supplemental oxygen is recommended only when saturation drops below 95%.

 

Original title: Oxygen Therapy in Suspected Myocardial Infarction.

Presenter: Hofmann R.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...